Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.30
+0.48 (3.24%)
Sep 15, 2025, 2:07 PM EDT - Market open

Company Description

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.

It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.

The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Limited
Mesoblast logo
CountryAustralia
Founded2004
IndustryBiotechnology
SectorHealthcare
Employees81
CEOSilviu Itescu

Contact Details

Address:
55 Collins Street, Level 38
Melbourne, VIC 3000
Australia
Phone61 3 9639 6036
Websitemesoblast.com

Stock Details

Ticker SymbolMESO
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001345099
CUSIP Number590717104
ISIN NumberUS5907174016
SIC Code2836

Key Executives

NamePosition
Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board and Executive Director
Dr. Eric A. Rose M.D.Chief Medical Officer and Executive Director
Andrew Chaponnel B.Com.Interim Chief Finance Officer
Peter T. Howard B.Sc., L.L.B.General Counsel and Corporate Executive
Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs and Quality Management
Justin Horst B.S.Head of Manufacturing
Dr. Fiona See Ph.D.Senior Vice President and Head of Translational Research
Marcelo SantoroChief Commercial Officer
Niva Sivakumar B.Com., L.L.B.Joint Company Secretary

Latest SEC Filings

DateTypeTitle
Sep 15, 20256-KReport of foreign issuer
Sep 15, 20256-KReport of foreign issuer
Sep 12, 2025SCHEDULE 13G/AFiling
Sep 4, 20256-KReport of foreign issuer
Aug 29, 20256-KReport of foreign issuer
Aug 29, 202520-FAnnual and transition report of foreign private issuers
Aug 27, 20256-KReport of foreign issuer
Jul 18, 20256-KReport of foreign issuer
Jul 15, 20256-KReport of foreign issuer
Jul 1, 20256-KReport of foreign issuer